INNO — Innocan Pharma Balance Sheet
0.000.00%
Last trade - 00:00- CA$47.87m
- CA$43.51m
- $29.44m
- 76
- 41
- 18
- 41
Annual balance sheet for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.34 | 11 | 4.95 | 3.88 | 5.01 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.13 | 0.169 | 0.243 | 0.694 | 0.536 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.28 | 12.5 | 6.88 | 6.8 | 9.15 |
| Net Property, Plant And Equipment | 0.056 | 0.054 | 0.098 | 0.136 | 0.113 |
| Total Assets | 4.33 | 12.6 | 6.98 | 6.94 | 9.26 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.94 | 3.56 | 0.731 | 2.54 | 2.24 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 7.94 | 3.52 | 0.582 | 2.84 | 4.09 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.61 | 9.05 | 6.39 | 4.1 | 5.17 |
| Total Liabilities & Shareholders' Equity | 4.33 | 12.6 | 6.98 | 6.94 | 9.26 |
| Total Common Shares Outstanding |